Opinion|Videos|October 28, 2024
Incorporating Real-World Evidence for HER2+ NSCLC
Key Takeaways
- Real-world evidence enhances understanding of HER2-directed therapies' effectiveness and safety in diverse populations, complementing clinical trial data.
- Collaboration among payers, providers, and manufacturers is vital for equitable access to HER2-directed therapies and cost management.
Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
- (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
5 Things to Know About the 2026 ESC Heart Failure Guidelines
5